ArticleCell death discovery2026
Multi-omic profiling reveals metabolic vulnerabilities in enzalutamide resistant prostate cancer.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Resistance to the androgen receptor inhibitor enzalutamide (ENZ) is a major barrier to durable control of advanced prostate cancer. Given the central role of metabolic reprogramming in tumour survival under therapeutic stress, we investigated whether ENZ resistance is associated with adaptive metabolic rewiring that promotes stress tolerance and evasion of cell death. Multi-omic profiling of ENZ-sensitive (C4-2B and V16D) and ENZ-resistant (MR49F) cells revealed extensive metabolic reprogramming, with lipid metabolism emerging as a dominant axis. ENZ-resistant cells displayed depletion of long-chain polyunsaturated fatty acids (PUFAs) and increased resistance to lipid peroxidation and ferroptosis. Restoring PUFA availability or activating lipid regulatory pathways via treatment with a liver X receptor (LXR) agonist re-sensitised resistant cells to ferroptotic cell death. In parallel, nitrogen metabolism was altered in ENZ-resistant cells, including increased carbamoyl phosphate synthetase 1 (CPS1) and resistance to ammonium exposure. Treatment with the CPS1 inhibitor H3B-120 reduced proliferation of MR49F cells and increased their sensitivity to ammonium stress. Together, these findings identify coordinated lipid and nitrogen remodelling as targetable metabolic adaptations that support resistance to cellular stress and death in ENZ-resistant prostate cancer cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.